In the first quarter, Huiyang Medical obtained registration certificates for two innovative medical devices, forming China's first RF-cross® Radiofrequency Atrial Septal Puncture System with "Zero Exchange, Mechanical + Radiofrequency Dual Technology, and Compatibility with Adjustable Bending." In 2024, it entered the National "Special Review Channel for Innovative Medical Devices" and has now initiated the commercialization process, offering the potential to provide a safer and more controllable domestically produced solution for cardiac interventional surgeries. Atrial septal puncture is a commonly used technique in left atrial interventional treatments. Taking atrial fibrillation (AF) treatment as an example, the number of AF patients in China is vast and continuously growing, with the volume of AF ablation surgeries constantly rising, driving the market demand growth for core devices such as puncture needles and puncture sheaths used in atrial septal puncture procedures. However, the current clinically prevalent mechanical puncture methods have shortcomings, including high operational difficulty, a steep learning curve for doctors, potential severe complications, challenges in precisely predicting the puncture site, and time-consuming puncture processes.

At this year's CMEF, AI has permeated every corner of medical devices, with Deepwise completing a transformation from technology-centric to clinically-focused. By reshaping the AI empowerment pathway through scenario-based thinking, it builds AI tailored to specific diseases and around the entire clinical diagnosis and treatment process, offering departments comprehensive solutions—fundamentally different from single-point AIs in the market. At this CMEF, Deepwise launched its multimodal clinical intelligence platform, Deepwise MetAI X, positioned as an all-hospital-level multimodal intelligent hub and digital intelligence foundation. Relying on a "dual-bus" architecture and dual AI engines for "imaging + text," it can centrally manage multimodal imaging data, deeply integrate key processes, form an end-to-end intelligent service system, and reconstruct the operational logic of radiology departments. Its core breakthrough lies in AI-native integration, being both scalable and expandable, providing hospitals with a one-stop intelligent imaging hub.

Clinical-stage biopharmaceutical company Parabilis Medicines (formerly FogPharma) announced the completion of a $305 million Series F financing round, co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors, with participation from Frazier Life Sciences, Soleus Capital, and other institutions. The financial advisor was not mentioned. Following this round of financing, Parabilis has cumulatively raised $801 million. Since its establishment, the company has focused on the field of oncology, founded by Harvard chemist Dr. Gregory Verdine, who has established more than 10 biotech companies, in collaboration with the former head of global R&D at Johnson & Johnson. Their aim is to address the challenge in cancer treatment where "targets are identifiable, but drugs are difficult to develop," by creating new drugs capable of penetrating cell membranes and precisely binding to flat intracellular targets.

Gilead Sciences, Not Content as HIV Leader, Shows Strong Ambition in Oncology. On April 9, it secured global development rights for KT-200. The original developer, Kymera, will receive a $45 million milestone payment and is eligible for substantial total payments and tiered royalties. On the 100th day of 2026, Gilead made its fourth move, with a potential total deal value of approximately $15.725 billion, including the acquisition of CAR-T company Arcellx, the merger with Ouro Medicines, and the purchase of Germany's next-generation ADC company Tubulis Technologies. KT-200, the subject of this transaction, is the world’s first oral molecular glue degrader targeting CDK2, which selectively eliminates CDK2, a key driver of tumor growth, offering a more precise, safe, and effective oral treatment option for cancers dependent on CDK2 activity. Preclinical tests have shown strong activity, potential for brain penetration, and good safety.

On April 10, 2026, it was reported that *Radiology*, the top international journal in radiology, published a highly anticipated prospective clinical study. The study focused on the clinical performance of using "dual-ring phased array static CT" for diagnosing small pulmonary nodules. The research demonstrated that the dual-ring phased array static CT, independently developed by Beijing Nano-dimensional King Technology Co., Ltd., performed exceptionally well in detecting small nodule lesions. With an ultra-fine slice thickness of 0.165mm and tens of millions of pixel-level imaging, the device can clearly capture pathological details of terminal bronchioles at levels 9 to 12 and small nodule lesions. The achievement of extremely high-resolution imaging is due to the reconstruction of the imaging logic. The dual-ring phased array static CT abandons the principle of "mechanical rotation" imaging and instead adopts "optical rotation" imaging, completing 360° data acquisition through sequential pulse exposure from numerous X-ray sources on a ring gantry, completely eliminating the centrifugal force limitations and artifacts caused by mechanical rotation. In the study, the phased array CT was compared with globally leading high-end spiral CTs. The results showed that while traditional CTs could only visualize bronchi up to level 7, the phased array CT could display terminal bronchioles at levels 9 to 12; among 11 pulmonary structures, the visibility scores for 8 structures significantly surpassed those of traditional devices.

As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo(Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.

The significant scale increase of this current round signals that NorrDia Medical has formally transitioned from a single-line focus on acute critical care into a new stage of platform-based development, characterized by the synergistic advancement of both acute and chronic disease portfolios, driven by a dual-engine approach in both domestic and international markets.

On April 7, Ammunition submitted its second application for a main board listing on the Hong Kong Stock Exchange, with joint sponsors being CCB International and BOCOM International. In 2015, founder Zhang Lianglu gave up the pan-cancer screening trend and focused on DNA methylation testing for high-incidence cancers and the qPCR platform, pursuing a differentiated path. In 2022, the colorectal cancer detection product "Aichangkang" obtained Class III certification and achieved commercialization; in 2025, Ammunition will have a "big year" of obtaining certifications, acquiring three Class III certificates within one year, accumulating five in total, ranking first among domestic methylation early screening companies. Currently, Ammunition has developed more than 10 cancer early screening products, with five approved as Class III medical devices, covering four major high-incidence cancers. "Aixinggan" and "Aiguangle" are the core pillar products, where "Aixinggan" is the world's first liver cancer early screening Class III certified product based on qPCR technology, with an overall sensitivity of 92.3%. The supplementary financial data from the second submission is impressive, but cash reserves are under pressure, making the listing on the secondary market a critical step for the company at this stage.

The rapid advancement of technologies such as minimally invasive interventions, coupled with increased disease awareness among patients, has led to a sharp rise in the demand for pan-vascular interventional diagnosis and treatment. This, in turn, has driven a rapid increase in the demand for medical devices used in diagnostic and treatment services, thereby accelerating the expansion of the pan-vascular interventional device market.

FORE Biotherapeutics, a cancer-targeted therapy company, announced that its self-developed novel BRAF inhibitor, plixorafenib, has received Breakthrough Therapy Designation from the FDA for the treatment of adult patients with high-grade glioma (HGG) carrying the BRAF V600E mutation. This marks the world's first targeted therapy for HGG to receive such a designation. BRAF is a kinase in the MAPK pathway, and the V600E mutation accounts for 90% of BRAF variations, appearing in various types of brain tumors and increasing the risk of low-grade gliomas progressing to HGG. Traditional BRAF inhibitors have limitations, including insufficient anti-tumor activity against BRAF dimers or Class 2 mutations and causing "paradoxical activation," which leads to treatment resistance. Plixorafenib, as a new oral small-molecule BRAF inhibitor, demonstrates high selectivity for BRAF mutations, and its design mechanism addresses the limitations of the previous two generations of drugs.